Revisiting Cancer Diagnosis in Scotland: Further Insights from the Second Scottish National Cancer Diagnosis Audit

Table 5

Diagnostic interval descriptive statistics with percentages of patients with DI of >60 and >90 days for 2019 (excluding screen detected).

	Total	Missing	Diagnostic interval	DI > 60 days	DI > 90 days
	N	N	Median days (25th–75th centile)	%	%
Total	2125	414	27 (10–59)	24.5	16.2
Sex
Male	1092	238	30 (11–70)	28.2	19.2
Female	1033	176	23 (9–48)	20.9	13.2
Age categories (years)
0–24	26	4	22 (7–49)	n < 5	n < 5
25–49	197	21	25.5 (10–51.5)	20.5	11.9
50–64	519	79	25 (12–56)	23.2	13.2
65–74	642	124	29 (11–70)	27.8	20.5
75–84	551	133	23 (7–53)	22.2	13.6
≥85	190	53	27 (7–88)	30.7	24.8
Cancer site categories
Bladder	59	7	27.5 (8.5–68)	25	19.2
Brain	37	7	16.5 (0–43)	20	13.3
Breast	211	19	20 (11.5–35)	7.8	4.2
Colon	170	27	32 (12–76)	31.5	21.7
Gynae–other	88	8	24.5 (12.5–52)	18.8	10
Leukaemia	45	9	7 (2.5–33)	19.4	13.9
Liver and bile tract	54	22	17.5 (1.5–34)	12.5	9.4
Lung and bronchus	371	93	17 (3–44)	18.7	11.5
Lymphoma	101	19	33 (15–76)	28	19.5
Melanoma	117	10	21 (13–49)	21.5	9.3
Multiple myeloma	30	7	37 (20–77)	34.8	17.4
Oesophageal	62	7	28 (12–71)	27.3	12.7
Oral/oropharyngeal	72	24	35.5 (15.5–97.5)	37.5	27.1
Others	108	23	30 (10–67)	30.6	17.6
Ovarian	45	8	21 (8–47)	21.6	8.1
Pancreas	50	6	12.5 (1.5–35)	13.6	9.1
Prostate	288	70	44.5 (23–105)	36.7	27.5
Rectal	69	13	40.5 (19–122)	35.7	30.4
Renal	71	21	36.5 (9–94)	42	28
Stomach and small intestine	68	11	20 (3–56)	24.6	21.1
Unknown primary	9	3	34 (14–55)	16.7	16.7
Comorbidity category
No comorbidities	526	71	28 (13–53)	22.2	13.6
1 comorbidity	625	100	23 (10–58)	24	16
2 comorbidities	470	100	22.5 (7–51)	21.6	14.9
≥3 comorbidities	481	133	31.5 (10.5–78)	31.3	21
Patient SIMD at diagnosis
1	417	103	22 (8–55)	23.2	11.1
2	404	74	25 (8–56)	22.7	16.1
3	415	75	29.5 (11.5–63.5)	26.2	19.4
4	392	74	27 (10–61)	25.2	14.5
5	482	86	28 (12–62.5)	25.8	19.2
2-fold urban rural classification
Urban	1655	333	25 (10–56)	23.8	15.7
Rural	449	78	33 (12–70)	28	18.6